Shin Splints Is the Wrong Name: MTSS as the Mild End of a Bone-Stress Continuum

A second-year medical student walks into clinic, twenty-eight kilometres into a marathon build, with two weeks of vague shin ache that became sharp last Saturday. You palpate. Diffuse tenderness along the middle-to-distal third of the posteromedial tibia, maybe four to five centimetres of it, no focal point. Hop test on the affected leg reproduces pain at a five out of ten — uncomfortable but not catastrophic. You diagnose medial tibial stress syndrome, draft a deload, schedule a review in three weeks.

Eight weeks later the same patient is in an orthopaedic registrar’s clinic with a confirmed mid-shaft tibial stress fracture on MRI, having pushed through what she — and reasonably you — assumed was shin splints.

This pattern is common enough that it should change how we think about the diagnosis. MTSS is not a benign muscular condition that occasionally gets worse. It is, on the best available evidence, the mild end of a bone-stress continuum that includes periosteal reaction, cortical stress reaction, and frank stress fracture. The clinical label we use shapes how aggressively we deload — and how often we miss the transition.

What MTSS Is, and What It Isn’t

The old framing — “tibial periostitis,” shin splints as a muscle problem — does not hold up. Magnetic resonance imaging in symptomatic athletes consistently shows periosteal oedema and bone marrow oedema along the posteromedial tibia, often without overt cortical disruption. The pain is bone pain, dressed in muscular clothing.

Warden, Davis and Fredericson (2014, JOSPT) made the case directly: tibial bone stress injury exists as a spectrum of impairments that includes MTSS at the lower-symptom end, tibial stress reaction in the middle, and tibial stress fracture at the severe end. The histology is not identical at every point — there is genuine debate about whether MTSS is best modelled as the earliest stage of a continuum or as a distinct entity that overlaps clinically with bone stress injury — but the practical implication is the same. Whatever you call it, the affected tissue is the bone–periosteum interface, and the driver is cumulative mechanical load exceeding remodelling capacity.

A 2023 BJSM paper from Hoenig, Tenforde, Warden and colleagues went further, arguing that the current terminology is itself the problem: “stress fracture” implies a binary state when what we see is a continuum of bone overuse, and clinicians need a language that captures gradation. Their suggestion — distinguishing between bone stress reaction and bone stress fracture — has not been universally adopted, but the conceptual shift is sound and worth adopting in your own clinical reasoning even if you keep the older labels in your notes.

What MTSS is not: it is not a problem you train through; it is not adequately explained by tibialis posterior dysfunction (Beck and Osternig demonstrated in 1994 that tibialis posterior has no consistent attachment to the posteromedial tibia at the symptomatic site); and it is not a condition where soft-tissue work alone resolves the underlying load problem.

The Soleus Is the Mechanistic Substrate

If you take one thing from this article, take this. The soleus, not the tibialis posterior, is the muscle whose periosteal attachment most closely overlies the MTSS pain site.

Beck and Osternig’s cadaveric work, later confirmed by Brown’s 2016 anatomical review (Scientifica), traced the muscular attachments along the posteromedial tibia at the symptomatic zone. The fibres found attaching directly to the posteromedial border were the soleus and flexor digitorum longus. Tibialis posterior — the textbook villain — was conspicuously absent from this region.

Mechanistically, this matters. The soleus is the dominant Achilles load-bearer during slow running and walking, generating peak forces that exceed the gastrocnemius across stance. Its periosteal attachment along the posteromedial tibia transmits that tension directly to bone. Repetitive high-load contractions during running produce cyclic periosteal traction at exactly the site where MTSS pain localises. The bone marrow oedema seen on MRI is the bone’s response to that load.

The clinical translation is uncomfortable for conventional rehab. Most MTSS programmes still centre on calf stretching, eccentric strengthening, foot intrinsic work and gradual mileage progression. These have merit — calf stiffness and arch mechanics do contribute. But if the soleus is generating excess traction at the symptomatic site, the most direct intervention is to reduce that traction during the period when the bone is trying to remodel. Stretching does not reduce active contraction load. Eccentric work, paradoxically, increases it.

We will come back to this.

Risk Factors: Who, and Why

Yates and White’s 2004 cohort of Royal Australian Navy recruits (American Journal of Sports Medicine) remains the cleanest prospective risk-factor study. They observed an MTSS incidence of 35% in female recruits and 20% in male recruits across a ten-week training block. Navicular drop and previous history of shin pain emerged as the most consistent independent predictors. The female-male disparity has been replicated, with hormonal contributors to bone remodelling capacity now better understood — relative energy deficiency in sport (RED-S) in particular sits behind a significant fraction of female athlete bone-stress injury that presents initially as “just shin splints.”

Newman, Witchalls, Waddington and Adams’ 2013 systematic review and meta-analysis in Open Access Journal of Sports Medicine synthesised the prospective evidence: significant associations were found between MTSS incidence and female sex, prior MTSS history, fewer years of running experience, orthotic use, elevated BMI, increased navicular drop, and increased hip external rotation in males.

What the risk-factor literature does not yet do well is quantify the dose. The training-error pathway — too much load applied too quickly to a bone that has not had time to adapt — remains the dominant clinical driver, and it interacts with intrinsic factors. A runner with a 9 mm navicular drop who increases weekly mileage by 8% per week and eats adequately may never present. The same runner adding 30% mileage in a single fortnight, on a low-energy-availability background, has stacked the loaded dice.

Tim Gabbett’s work on acute:chronic workload ratios is the practical framework here. Acute spikes (the most recent week’s load divided by the trailing four-week average) above 1.5 are consistently associated with elevated soft-tissue and bone-stress injury risk. The corollary — that high chronic workloads, accrued gradually, are protective — is the more useful clinical message for the runner asking “how do I avoid this next time?”

Imaging: When, and What You’ll Miss

The diagnostic question is rarely “is this MTSS?” The diagnostic question is “is this MTSS or stress fracture, and how far along the continuum?”

Plain radiographs are insensitive in the first three to four weeks. Periosteal reaction may eventually appear as a faint cortical thickening on lateral views, but a negative film does not exclude bone stress injury and routinely under-grades the lesion.

MRI is the modality of choice when the diagnosis matters — and it almost always does, because grading drives prognosis. The Fredericson grading system (Grade 1: periosteal oedema only; Grade 2: bone marrow oedema on T2; Grade 3: marrow oedema on T1 and T2; Grade 4: cortical fracture line) maps cleanly to expected return-to-run timelines, with Grade 1–2 typically resolving in three to six weeks of relative rest and Grade 3–4 requiring eight to sixteen weeks with much stricter loading restriction.

Practical rule: focal point tenderness reproducible at a single bony site, night pain, pain at rest, or a positive single-leg hop test should push you to MRI rather than empirical conservative management. Diffuse tenderness along three to five centimetres of posteromedial tibia, pain only with loading, negative hop — you can usually trial conservative management with a planned three-week review and low threshold for imaging if symptoms do not de-escalate.

Conservative Management: What Actually Works

The honest answer is that the evidence base is thinner than the breadth of recommended treatments suggests. Winters et al. (2013, Sports Medicine) systematically reviewed MTSS treatment and concluded that the existing evidence was of insufficient methodological quality to recommend any specific intervention. That review remains broadly accurate a decade later.

What we have:

Relative rest plus graded reloading is the backbone. Most clinicians use a reduction to pain-free loading volume, often 30–50% of prior weekly mileage with running replaced by aqua-jogging or cycling, then a graded return at 10–15% weekly increases — accepting that the 10% rule is heuristic, not generalisable.

Extracorporeal shockwave therapy has the best (still modest) evidence as an adjunct. Moen et al. (2012, BMC Sports Science, Medicine and Rehabilitation) ran a randomised trial in athletes comparing a graded running programme with and without focused shockwave, showing significantly faster return to full sport in the shockwave group. Subsequent military-population trials (Newman et al., Rompe et al.) and a 2017 single-blind cadet trial have been broadly supportive. The 2016 Gomez Garcia sham-controlled pilot was equivocal but underpowered. The reasonable clinical position: shockwave is worth considering as an adjunct in MTSS that has plateaued at two to three weeks of relative rest, not as primary therapy.

Calf strengthening, particularly soleus-biased (heavy slow resistance, isometric loading, bent-knee variants), is widely prescribed and probably useful for medium-term load tolerance — but the mechanism is building bone and tendon-unit capacity, not “treating” the acute lesion. Prescribe it for next season, not this fortnight.

Foot orthoses have inconsistent evidence and are best reserved for the navicular-drop subgroup.

Soft-tissue and dry needling around the medial gastrocnemius and soleus help symptoms in some patients without changing the underlying load story.

Return to Run: Criteria, Not Calendars

The scoping review by Wood et al. (2024, in PMC) on returning to running following tibial bone stress injury makes clear that no single criterion is well validated. A defensible composite:

• Pain-free single-leg hop, ten repetitions, both legs symmetric.
• Pain-free brisk walk for thirty minutes.
• No tenderness on palpation at the previously symptomatic site.
• For Grade 2+ bone stress injury, an interval running programme starting at run/walk ratios (commonly 1:4 progressing to 4:1 over four to six weeks) rather than continuous running.

Grade 1 MTSS without imaging-confirmed cortical involvement can usually return faster, but treat the return as a graded reload, not a resumption.

Three Clinical Patterns

Pattern one: the spike. Asymptomatic runner, sudden mileage or intensity jump (new training block, return from holiday, marathon build). Onset over one to three weeks. Usually responds well to a fortnight of relative rest and a structured deload. Educate on acute:chronic load ratio for next build.

Pattern two: the recurrent. Multiple previous episodes, often a high-arched or hyperpronating foot, often a runner who never fully completes the graded return before resuming full training. The bone never gets to remodel. Management is rarely about the current episode; it is about renegotiating their training architecture and treating the underlying capacity gap.

Pattern three: the masquerader. Initially looks like MTSS, but focal tenderness emerges or pain worsens despite deload. This is the patient who needs MRI early. Do not wait for the third visit.

Where the Sleeve Sits

Graded return-to-run and load monitoring are the cornerstones of MTSS management. They will remain so. The clinical question this section addresses is narrower: what does the patient do between rehab sessions, when their ambulatory dose — walking, standing, stairs, daily life — keeps loading the same periosteal site you are trying to let remodel?

That ambulatory dose is the gap most rehab programmes do not address. You can prescribe relative rest from running. You cannot prescribe relative rest from walking to the kitchen. The Pattern Two recurrent — the runner who has done everything right, deloaded properly, completed the return-to-run progression to specification, and still reaches threshold at week three of every rebuild — is, almost invariably, a patient whose tibia is not getting a quiet enough between-session window for remodelling to complete. The soleus keeps pulling on the same patch of posteromedial periosteum, all day, every day, in the background, regardless of what their structured rehab is doing.

The Orthopaedic Sleeve is the adjunct designed to address that gap. It is a calf compression sleeve developed with the University of Queensland, and its mechanism is mechanical: targeted compression of the gastrocnemius–soleus complex reduces neuromuscular drive and therefore active muscle tension during loading. Independent biomechanics testing finalised in the UQ Final Report (June 2025) quantified the effect across multiple loading conditions and reporting frames worth distinguishing carefully.

The group-level standing balance data: a 32% reduction in medial gastrocnemius EMG, significant at p=0.002, alongside an 8.1% reduction in modelled peak Achilles tendon force. This is the headline statistic and the one with the cleanest cohort-level inference.

The individual late-stance walking maxima — UQ Final Report §3.2.5 — are the more mechanistically relevant numbers for MTSS specifically. During the push-off phase of gait, individual participants showed reductions of up to 47.8% in lateral gastrocnemius EMG, 21.9% in medial gastrocnemius EMG, and 20.4% in soleus EMG. These are individual maxima rather than group means, and we say so explicitly — they describe the upper end of effect size rather than the typical patient. The clinically important number for MTSS is the soleus reduction, because the soleus is the muscle whose periosteal attachment most directly overlies the symptomatic zone. Every step, all day, with that level of reduction available, is a non-trivial reduction in cumulative periosteal traction at the site you are trying to let remodel.

That is the mechanistic case. The clinical evidence is more limited. There is no published randomised trial of the Sleeve in MTSS; we will not present one until there is. What we will say is this: the soleus is the most direct mechanical contributor to MTSS pathology, EMG-confirmed reduction of soleus activation during ambulatory loading is mechanistically aligned with the pathology, and the patient who is reaching the same threshold at the same point of every rebuild is the patient for whom an additional ambulatory-load intervention has the clearest theoretical rationale.

In clinic, position the Sleeve as the adjunct that addresses ambulatory soleus loading during the graded return-to-run window — the four-to-eight-week period when the bone is remodelling but the patient is back on their feet for everything other than running. It is not a substitute for the deload. It is not a substitute for the graded progression. It is the tool that closes the loop on the load you cannot otherwise prescribe away. For the Pattern One spike patient, conservative management without the Sleeve will usually be sufficient. For the Pattern Two recurrent — the patient who has done everything right but keeps reaching the same threshold — this is the clinical edge worth offering.

That recommendation is a mechanistic argument, not a trial finding. We will keep saying so until the data are in. But for the recurrent MTSS patient who has exhausted conventional rehab and is staring down another six-week deload, “mechanistically aligned and worth trying as an adjunct” is, honestly, where the evidence base for most MTSS interventions sits. Shockwave has thin RCT support. Foot orthoses are inconsistent. Calf eccentrics build capacity but increase acute load. The Sleeve is the only intervention that directly and measurably reduces soleus traction during the ambulatory window — and for the patient whose problem is ambulatory soleus traction during the ambulatory window, that alignment is worth your clinical attention.

Key References

• Warden SJ, Davis IS, Fredericson M. Management and prevention of bone stress injuries in long-distance runners. Journal of Orthopaedic & Sports Physical Therapy. 2014;44(10):749–765.
• Hoenig T, Tenforde AS, Strahl A, Rolvien T, Warden SJ. Does magnetic resonance imaging grading correlate with the time to return to sport following bone stress injury? British Journal of Sports Medicine. 2023.
• Yates B, White S. The incidence and risk factors in the development of medial tibial stress syndrome among naval recruits. American Journal of Sports Medicine. 2004;32(3):772–780.
• Newman P, Witchalls J, Waddington G, Adams R. Risk factors associated with medial tibial stress syndrome in runners: a systematic review and meta-analysis. Open Access Journal of Sports Medicine. 2013;4:229–241.
• Winters M, Eskes M, Weir A, Moen MH, Backx FJG, Bakker EWP. Treatment of medial tibial stress syndrome: a systematic review. Sports Medicine. 2013;43(12):1315–1333.
• Moen MH, Rayer S, Schipper M, et al. Shockwave treatment for medial tibial stress syndrome in athletes: a prospective controlled study. British Journal of Sports Medicine. 2012.
• Beck BR, Osternig LR. Medial tibial stress syndrome: the location of muscles in the leg in relation to symptoms. Journal of Bone and Joint Surgery. 1994;76(7):1057–1061.
• University of Queensland. The Orthopaedic Sleeve: Biomechanics Final Report. June 2025. Group standing balance medial gastrocnemius EMG reduction 32% (p=0.002); modelled peak Achilles tendon force reduction 8.1%; §3.2.5 individual late-stance walking EMG maxima — lateral gastrocnemius 47.8%, medial gastrocnemius 21.9%, soleus 20.4%.